WO2016108654A1 - Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도 - Google Patents
Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도 Download PDFInfo
- Publication number
- WO2016108654A1 WO2016108654A1 PCT/KR2015/014542 KR2015014542W WO2016108654A1 WO 2016108654 A1 WO2016108654 A1 WO 2016108654A1 KR 2015014542 W KR2015014542 W KR 2015014542W WO 2016108654 A1 WO2016108654 A1 WO 2016108654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- fusion polypeptide
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 150
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 128
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 122
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 32
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 32
- 230000004927 fusion Effects 0.000 claims abstract description 104
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 77
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims abstract description 59
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 45
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 40
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 36
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 35
- 102000004190 Enzymes Human genes 0.000 claims abstract description 34
- 108090000790 Enzymes Proteins 0.000 claims abstract description 34
- 238000002512 chemotherapy Methods 0.000 claims abstract description 32
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims abstract description 30
- 230000001965 increasing effect Effects 0.000 claims abstract description 28
- 206010049416 Short-bowel syndrome Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims abstract 4
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 claims description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 80
- 230000000968 intestinal effect Effects 0.000 claims description 27
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 20
- 201000010927 Mucositis Diseases 0.000 claims description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 150000007523 nucleic acids Chemical group 0.000 claims description 20
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 108091033319 polynucleotide Proteins 0.000 claims description 15
- 102000040430 polynucleotide Human genes 0.000 claims description 15
- 239000002157 polynucleotide Substances 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 42
- 229940079593 drug Drugs 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 8
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 153
- 235000001014 amino acid Nutrition 0.000 description 66
- 229940024606 amino acid Drugs 0.000 description 62
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 58
- 150000001413 amino acids Chemical class 0.000 description 41
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
- 238000010586 diagram Methods 0.000 description 15
- 229940121355 glucagon like peptide 2 (glp-2) analogues Drugs 0.000 description 15
- 210000000813 small intestine Anatomy 0.000 description 15
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 235000004279 alanine Nutrition 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 13
- 239000008103 glucose Substances 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 102200069889 rs104893964 Human genes 0.000 description 12
- 102220074722 rs796053167 Human genes 0.000 description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000004471 Glycine Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
- 230000004580 weight loss Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 6
- 102000009490 IgG Receptors Human genes 0.000 description 6
- 108010073807 IgG Receptors Proteins 0.000 description 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 6
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000013222 sprague-dawley male rat Methods 0.000 description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- -1 GLP-1 (7-36) amides Chemical class 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 230000003914 insulin secretion Effects 0.000 description 5
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- CILIXQOJUNDIDU-ASQIGDHWSA-N teduglutide Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 CILIXQOJUNDIDU-ASQIGDHWSA-N 0.000 description 5
- 229960002444 teduglutide Drugs 0.000 description 5
- 208000004232 Enteritis Diseases 0.000 description 4
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000008556 epithelial cell proliferation Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 3
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 3
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 3
- 102100032879 Glucagon-like peptide 2 receptor Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 3
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108010058003 Proglucagon Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 108010073046 teduglutide Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 101500028771 Homo sapiens Glucagon-like peptide 2 Proteins 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 description 1
- 229950010221 alexidine Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- UKVFVQPAANCXIL-FJVFSOETSA-N glp-1 (1-37) amide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 UKVFVQPAANCXIL-FJVFSOETSA-N 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001134 intestinotrophic effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000021238 nutrient digestion Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044697 tropical sprue Diseases 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a glucagon like peptide (GLP) and an immunoglobulin hybrid Fc fusion polypeptide, more particularly an increase in half-life compared to conventional fusion polypeptides, based on the discovery of immunoglobulin hybrid Fc suitable for GLP or analogs thereof.
- GLP glucagon like peptide
- polynucleotides encoding the fusion polypeptide
- expression vectors comprising the polynucleotides
- host cells comprising the expression vectors.
- Diabetes mellitus is a metabolic disorder that causes hyperglycemia, a condition in which insulin secretion or insulin function is caused by genetic or environmental causes and glucose in the blood is not a cell energy source and remains high in the blood. Accompanying is the most serious chronic disease in modern times.
- IBD inflammatory bowel disease
- Ulcerative colitis is a chronic inflammatory disease of the large intestinal mucosa of the digestive tract. Inflammation begins in the rectum and continues into the upper colon. Patients complain of diarrhea, bloody stools, and abdominal pain, which are relatively common symptoms such as loss of appetite, weight loss, and fatigue. In most cases, symptoms worsen and improve, and sometimes there are periods of no symptoms for a very long time.
- CD Crohn's disease
- ulcerative colitis Crohn's disease
- Symptoms include diarrhea, abdominal pain and loss of appetite, and the types and extent of symptoms vary greatly from patient to patient, and many patients experience more pain than ulcerative colitis and worsen long-term course and response to treatment. There are many cases.
- Gattex teduglutide
- cancer cells are characterized by rapid proliferation and division, most anticancer drugs are made to kill fast growing cells.
- normal cells are also damaged during chemotherapy.
- rapidly dividing cells that is, blood cells formed in the bone marrow, epithelial cells of the gastrointestinal tract including the oral cavity, hair cells, and germ cells that produce sperm and eggs are affected.
- anti-cancer drugs often cause mucositis of the gastrointestinal tract. In this case, diarrhea is caused.
- fluids and nutrients should be supplied by intravenous injection to prevent dehydration. This has a huge impact on cancer treatment when it is necessary to change the scheduled chemotherapy schedule.
- GLP-2 can induce proliferation of crypts cells that form villus of small intestine cells and can quickly heal side effects caused by chemotherapy, and the development of long-lasting GLP-2 analogues is anticancer chemotherapy 1
- One injection per cycle can prevent intestinal mucositis and diarrhea caused by chemotherapy.
- the inventors of the present invention in order to increase the half-life of short-length peptides containing GLP, such as GLP-1 or GLP-2 to develop a long-lasting therapeutic agent, in the prior patents of the present inventors International Patent Publication No. WO2008-147143 Incorporating the prepared immunoglobulin hybrid Fc technology and selecting an immunoglobulin Fc specifically optimized for glucagon like peptide (GLP), the fused poly having excellent half-life and excellent resistance to the DPP-4 enzyme By preparing a peptide, the present invention was completed.
- Another object of the present invention is to provide a pharmaceutical composition for treating intestinal mucositis and diarrhea or short bowel syndrome by diabetes, inflammatory bowel disease, chemotherapy, comprising the fusion polypeptide as an active ingredient.
- the fusion polypeptide of the present invention has an increased half-life compared to the existing GLP-1 or GLP-2, and has excellent resistance to the DPP-4 enzyme, thereby preventing intestinal mucositis caused by diabetes, inflammatory bowel disease, and chemotherapy. And diarrhea, or short bowel syndrome in the treatment of excellent drug efficacy compared to existing drugs, can be usefully applied to medicines.
- 1 is a diagram of the preparation of GLP-1-hyFc5, showing a schematic of GLP-1-hyFc5 and the sequence of GLP-1-hyFc5.
- FIG. 3 is a diagram of the preparation of GLP-2-hyFc9, showing a schematic of GLP-2-hyFc5 and GLP-2-hyFc9.
- Figure 4 is a graph confirming the PK profile of GLP-1 peptide and GLP-1-hyFc5.
- FIG. 5 is a graph of the PK profiles of GLP-1-hyFc5 and GLP-1-hyFc9, which is expressed as the amount of protein remaining in blood at each time and the area under the drug concentration curve (AUC).
- FIG. 6 is a diagram of the PK profiles of GLP-1-hyFc5, GLP-1-hyFc8 and GLP-1-hyFc9, and is represented by the amount of protein remaining in blood at each time.
- FIG. 7 is a diagram confirming the stability of the serum of GLP-1-hyFc5 and GLP-1-hyFc9, which is represented by the amount of protein remaining for each reaction time and the area under the curve (AUC) value of the time graph.
- FIG. 8 is a diagram confirming the DPP-4 resistance of GLP-1-hyFc5 and GLP-1-hyFc9, which is represented by the amount of protein remaining for each reaction time and the area under the curve (AUC) value of the time graph.
- FIG. 9 is a diagram of PD profiles of GLP-1-hyFc5 and GLP-1-hyFc9. The concentration of glucose in blood was measured to obtain an AUC value, which is expressed as% of AUC compared to a negative control.
- FIG. 10 is a diagram confirming the weight loss efficacy of GLP-1-hyFc9, showing the weight change and cumulative dietary intake.
- FIG. 11 is a diagram comparing the ADCC inhibitory ability of GLP-1-hyFc9 and GLP-1-linker-IgG4-mut, confirming the binding capacity to the Fc ⁇ receptor.
- FIG. 14 is a diagram confirming the effect of induction of intestinal epithelial cell proliferation of GLP-2-2G and GLP-2-hyFc9.
- 16 is a diagram confirming the diarrhea reduction effect of GLP-2-hyFc9, showing a diarrhea reduction effect induced by 5-FU.
- 17 is a diagram confirming the effect of reducing the mortality of GLP-2-hyFc9, showing the effect of reducing the mortality caused by diarrhea induced by 5-FU.
- the present invention provides in one embodiment (a) GLP or an analog thereof; And (b) an immunoglobulin Fc polypeptide comprising a limited number of IgD hinge regions.
- the fusion polypeptide may comprise (a) GLP or an analog thereof; (b) an immunoglobulin Fc polypeptide, wherein said immunoglobulin Fc polypeptide comprises (i) an isolated IgD hinge region consisting of 35 to 49 contiguous amino acid sequences from the C-terminus of SEQ ID NO: 25; And (ii) a CH2 and CH3 region consisting of the amino acid sequence of SEQ ID 29.
- the GLP glucagon like peptide, glucagon-like peptide
- GLP-2 GLP-2
- GLP-1 and GLP-2 peptides have different mechanisms and roles in vivo, they are peptides produced from one mRNA precursor in the proglucagon gene, and have high homology of amino acid sequences and sites cleaved by DPP-4 enzymes. Since the hormones are the same and have similar molecular properties, GLP (glucagon like peptide) including GLP-1 or GLP-2 may be similarly applied in fusion of immunoglobulin Fc polypeptides. Specifically, the GLP may be applied with a similar form of hyFc upon fusion with a hybrid Fc (hybrid Fc, hyFc) polypeptide developed by the present inventors.
- hybrid Fc hybrid Fc
- GLP-1 glucagon like peptide-1
- incretin a hormone secreted by the digestive tract, and is secreted by L cells in the intestinal tract depending on ingestion to increase insulin secretion of the pancreas. It is a protein known to play a role in inhibiting the secretion of glucagon and thereby raising the post-prandial blood sugar level. As such, GLP-1 has been widely known for its use in treating diabetes, and has been reported to be involved in weight loss by participating in physiological control of appetite.
- the natural GLP-1 is processed in vivo such that the first six amino acids are cleaved from the molecule.
- the amino terminus of GLP-1 is designated as 7 and the carboxy-terminus as 37.
- substitution of the amino acid at position 8 may decrease the rate at which the DPP-4 enzyme inactivates GLP-1, and substitution of the amino acid at position 22 reduces the likelihood that the molecule will aggregate and increase the potency of the molecule.
- substitution of the amino acid at position 36 may reduce the risk of the fusion protein inducing a neutralizing immune response after repeated and sustained administration in humans.
- the present invention is not limited thereto, and may use analogues substituted with amino acids at positions 8, 22, and 36, and in addition, as disclosed in US Pat. No. 7,452,966 B2, etc. Analogs in the form of substitution of amino acids at positions can also be used.
- the GLP-1 analogue is SEQ ID NO: 2, 3, 4, 5, 6, 7 in the form of the substitution of amino acids 8, 22 and / or 36 from GLP-1 (7-37) , GLP-1 analogue having an amino acid sequence of 8, 9, 10, 11 or 12, wherein SEQ ID NO: 8 is substituted with amino acids 8, 22 and / or 36 from GLP-1 (7-36) It may be a GLP-1 analogue having an amino acid sequence of 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24. In addition, more preferably SEQ ID NO: 2, 3, 6, 7, 8, 9, 11, 12, 14, 15, 18, 19, 20, 21 wherein the amino acid No.
- GLP-1 analogue having an amino acid sequence of 23 or 24 most preferably a GLP-1 analogue having an amino acid sequence of SEQ ID NO: 2 in which alanine (A) amino acid number 8 is substituted with glycine (G) Can be.
- the GLP-1 analogue having the amino acid sequence of SEQ ID NO: 2 may be encoded by the nucleic acid sequence of SEQ ID NO: 34. In one embodiment of the present invention using the GLP-1 analogue having the amino acid sequence of SEQ ID NO: 2 was confirmed its efficacy. Variation positions of the GLP-1 analogs are summarized in the table below.
- GLP-2 glucagon like peptide-2
- GLP-2 glucagon like peptide-2
- Peptide hormone with amino acid SEQ ID NO: 44
- GLP-1 glucagon-like peptide-1
- auxintomodulin glycentin in response to nutrient digestion with ingestion of food.
- A leucine (L), the amino acid at position 17, is glutamic acid (E), alanine (A), the amino acid at position 19, is threonine (T), and arginine (R), the amino acid at position 20, is As lysine (K), aspartic acid (D) at amino acid position 21 is isoleucine (I), asparagine (N) at amino acid position 24 is alanine (A) or glutamic acid (E), position 28 Glutamine (Q), an amino acid of, may be substituted with alanine (A) or asparagine (N), and isoleucine (I), an amino acid at position 31, may be substituted or deleted with proline (P), and position 32
- the amino acid of threonine (T) may be deleted
- aspartic acid (D) amino acid at position 33 is asparagine (N) It may be substituted or deleted.
- the fusion polypeptide was prepared by fusing hyFc5 according to the immunoglobulin hybrid Fc technology prepared in the prior patent publication WO2008-147143 to the GLP-1 or GLP-2.
- hybrid in the present invention means that a sequence encoding two or more immunoglobulin Fc fragments of different origin is present in a single-chain immunoglobulin Fc fragment.
- immunoglobulin Fc fragment or “immunoglobulin Fc” includes the heavy chain constant region (CH) of immunoglobulins and does not include the variable and light chain constant regions (CL) of the heavy and light chains of immunoglobulins. Does not mean protein.
- the Fc may further include a hinge region, and may include heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3), but may or may not include heavy chain constant region (CH1). .
- Suitable immunoglobulin Fc polypeptides that can be fused to the GLPs or analogs thereof of the invention are characterized by comprising an IgD hinge region of 35 to 49 amino acids in length.
- the hinge region basically serves to maintain the structure by maintaining flexibility when combined with a biologically active molecule such as GLP-1 or GLP-2.
- an isolated IgD hinge region having 35 to 49 contiguous amino acid sequences from the C-terminus to the N-terminus among the amino acid sequence of SEQ ID NO: 25 (encoded with the nucleic acid sequence of SEQ ID NO: 36) that is the IgD hinge region It may include.
- IgD hinge region consisting of 35 consecutive amino acid sequences of the amino acid sequence of SEQ ID NO: 25, IgD hinge region consisting of SEQ ID NO: 26, 40 consecutive amino acid sequences SEQ ID NO: 27, IgD hinge consisting of 49 consecutive amino acid sequences
- the region is represented by SEQ ID NO: 28, wherein the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 26 represents the nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 37, and SEQ ID NO: 27 encodes the amino acid sequence of SEQ ID NO: 38, SEQ ID NO: 28
- the nucleic acid sequences are shown in SEQ ID NO: 39, respectively.
- Immunoglobulin Fc CH2 and CH3 regions bound to such IgD hinge regions in the present invention do not alter the pharmacokinetic and drug efficacy of the fusion polypeptides of the present invention or cause cytotoxicity such as ADCC and / or CDC. It can be used without limitation, but preferably, the hybrid Fc CH2 and CH3 regions of IgD and IgG4 developed by the inventors can be used. Specifically, the CH2 and CH3 regions consisting of the amino acid sequence encoded by the amino acid sequence of SEQ ID NO: 29 or the nucleic acid sequence of SEQ ID NO: 40 can be used.
- Immunoglobulin Fc polypeptides comprising an IgD hinge region and CH2 and CH3 regions can be joined to finally form the fusion polypeptide of the present invention.
- the fusion polypeptide may be composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 30 to 32, and more specifically, May be composed of the amino acid sequence of SEQ ID NO: 30 or 31, or may be composed of the amino acid sequence of SEQ ID NO: 31.
- the amino acid sequence of SEQ ID NO: 30 is 'GLP-1-hyFc8' in the form of combining the GLP-1 analogue of SEQ ID NO: 2, the IgD hinge region of SEQ ID NO: 26, and the CH2 and CH3 regions of SEQ ID NO: 29 of the present invention.
- the amino acid sequence of SEQ ID NO: 31 is a GLP-1-hyFc9 in a form in which the GLP-1 analogue of SEQ ID NO: 2, the IgD hinge region of SEQ ID NO: 27, and the CH2 and CH3 regions of SEQ ID NO: 29 are combined.
- the amino acid sequence of SEQ ID NO: 32 is a combination of the GLP-1 analogue of SEQ ID NO: 2, the IgD hinge region of SEQ ID NO: 28, and the CH2 and CH3 regions of SEQ ID NO: 29; It is represented by -hyFc11 '.
- the fusion polypeptide may be composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 47 to 49, and more specifically, SEQ ID NO: 48 Or an amino acid sequence of 49 or an amino acid sequence of SEQ ID NO: 49.
- the amino acid sequence of SEQ ID NO: 47 is 'GLP-2-hyFc8' in the form of combining the GLP-2 analogue of SEQ ID NO: 45, the IgD hinge region of SEQ ID NO: 26, and the CH2 and CH3 regions of SEQ ID NO: 29 of the present invention.
- the amino acid sequence of SEQ ID NO: 48 is a GLP-2-hyFc9 in a form in which the GLP-2 analogue of SEQ ID NO: 45, the IgD hinge region of SEQ ID NO: 27, and the CH2 and CH3 regions of SEQ ID NO: 29 are combined.
- the amino acid sequence of SEQ ID NO: 49 is a GLP-2 analogue of GLP-2 analogue of SEQ ID NO: 45, an IgD hinge region of SEQ ID NO: 28, and a CH2 and CH3 region of SEQ ID NO: 29 It is represented by -hyFc11 '.
- the present inventors prepared GLP-1-hyFc5 by combining hyFc5 including an IgD hinge region consisting of 30 amino acid sequences developed by the present inventors to GLP-1 (FIG. 1), and a half-life thereof.
- hyFc5 including an IgD hinge region consisting of 30 amino acid sequences developed by the present inventors to GLP-1 (FIG. 1)
- the half-life increased.
- the half-life increase effect of applying hyFc5 to GLP-1 which is a short peptide, was not as high as the effect of applying hyFc5 to large protein.
- the present inventors have sought to find immunoglobulin Fc polypeptides that show better efficacy than hyFc5 when applied to GLP-1, and as a result, for short peptides such as GLP-1 or GLP-2, It has been found that increasing the length allows the preparation of fusion polypeptides with good activity with good half-life. That is, the IgD hinge region has a cleavage site sensitive to the enzyme, which is easily degraded by protease, and the cleavage site is exposed when the size of the bioactive protein bound to the immunoglobulin Fc polypeptide is large.
- hyFc9 having an IgD hinge region consisting of 40 amino acid sequences was prepared (FIG. 2), and based on this, hyFc8 having an IgD hinge region consisting of 35 amino acid sequences and 49 amino acid sequences.
- HyFc11 having the constructed IgD hinge region was prepared, and finally GLP-1-hyFc9, GLP-1-hyFc8 and GLP-1-hyFc11 fusion polypeptides were prepared.
- the PK profiles of the fusion polypeptides of the present invention prepared above have a much higher half-life than GLP-1-hyFc5 as well as peptides of GLP-1 alone (FIGS. 5 and 6), which are more effective. It was confirmed that the drug efficacy can be shown.
- GLP-1-hyFc9 was compared with the conventional GLP-1-hyFc5 and various effects, and resulted in serum stability (FIG. 7) and DPP-4 resistance (FIG. 8). ) And excellent in all aspects of the PD profile (FIG. 9). In addition, it was confirmed that the weight loss effect is also excellent (Fig. 10).
- the GLP-1-hyFc9, GLP-1-hyFc9 ADCC inhibitory result of comparing the GLP-1-linker-IgG4-mut (US Pat. No. 7,452,966 B2) and ADCC inhibitory ability, It was confirmed that the inhibitory ability is excellent (Fig. 11). Although the GLP-1-linker-IgG4-mut substantially changes the amino acid region of the immunoglobulin Fc to prevent ADCC, GLP-1-hyFc9 of the present invention has a superior ADCC inhibitory ability. .
- a fusion polypeptide was prepared for GLP-2, similarly to GLP-1.
- GLP-2-hyFc9 having an IgD hinge region consisting of 40 amino acid sequences was prepared (FIG. 3), and GLP-2-hyFc8 and 49 amino acids having an IgD hinge region consisting of 35 amino acid sequences were based on this.
- GLP-2-hyFc11 was prepared having an IgD hinge region composed of sequences. It was confirmed that GLP-2-hyFc9 in the prepared fusion polypeptide has an increased half-life compared to GLP-2-hyFc5 (Example 2-4).
- cAMP activity that can reduce inflammation is not reduced (Fig. 12), inflammatory bowel disease treatment effect (Fig. 13) Intestinal epithelial cell proliferation induction effect (FIG. 14), small intestine growth promoting effect (FIG. 15), diarrhea and lethality reduction effect (FIG. 16 and 17) were all excellent, and in spite of less treatment than the comparison group And it was confirmed that excellent efficacy is maintained.
- the fusion polypeptide of the present invention has an increased half-life compared to the existing GLP-1 or GLP-2, in particular the fusion polypeptide containing GLP-1 has excellent blood sugar lowering efficacy, weight It has a decreasing effect and resistance to the DPP-4 enzyme, and thus can be useful for treating diabetes mellitus, and the fusion polypeptide including GLP-2 has an effect of promoting small intestine growth, thereby inducing inflammatory bowel disease and intestinal mucositis caused by chemotherapy. And diarrhea or short bowel syndrome.
- the present invention provides a pharmaceutical composition for treating diabetes, and inflammatory bowel disease, intestinal mucositis and diarrhea caused by chemotherapy, or a short bowel syndrome in another embodiment, comprising the fusion polypeptide as an active ingredient.
- a pharmaceutical composition for treating diabetes, and inflammatory bowel disease, intestinal mucositis and diarrhea caused by chemotherapy, or a short bowel syndrome in another embodiment, comprising the fusion polypeptide as an active ingredient.
- the present invention provides a method for treating intestinal mucositis and diarrhea or short bowel syndrome by diabetes, inflammatory bowel disease, chemotherapy, comprising administering the pharmaceutical composition to a subject.
- the diabetes may be type 2 diabetes
- the inflammatory bowel disease may be ulcerative colitis or Crohn's disease.
- the intestinal mucositis and diarrhea may be caused by chemotherapy, wherein the chemotherapy is not limited to any chemotherapy that can cause intestinal mucositis and diarrhea, for example 5-fluorouracil (5- FU), irinotecan, leucovorin or oxaliplatin.
- chemotherapy is not limited to any chemotherapy that can cause intestinal mucositis and diarrhea, for example 5-fluorouracil (5- FU), irinotecan, leucovorin or oxaliplatin.
- the fusion polypeptide of the present invention can be usefully used in the treatment of diabetes by including GLP-1 or an analog thereof, which is widely known as a diabetes treatment agent, and with an increased half-life compared to conventional drugs, excellent blood sugar It has a lowering potency and has increased resistance to the DPP-4 enzyme, so that it can be applied to medicines with a better profile than existing drugs.
- the fusion polypeptide of the present invention includes GLP-2 or an analog thereof which is widely known as an agent for treating inflammatory bowel disease, intestinal mucositis and diarrhea by chemotherapy, or short bowel syndrome. It may be useful for the treatment of intestinal mucositis and diarrhea or short bowel syndrome by chemotherapy, and has an increased half-life compared to conventional drugs, and thus may be applied to medicines with a superior profile than existing drugs.
- the fusion polypeptides of the invention can be used to treat a wide variety of diseases and conditions.
- GLP-1 when the GLP included in the fusion polypeptide of the present invention is GLP-1, it exerts their biological effects by acting on a receptor primarily referred to as the "GLP-1 receptor".
- GLP-1 receptor a receptor primarily referred to as the "GLP-1 receptor".
- a subject having a disease and / or condition that responds favorably to administration of GLP-1 receptor stimulation or GLP-1 compound may be treated with the fusion polypeptide of the invention.
- These subjects are said to "require treatment with GLP-1 compounds” or "need GLP-1 receptor stimulation.”
- Subjects with functional dyspepsia and irritable bowel syndrome (see WO 99/64060). Also included are subjects requiring prophylactic treatment with GLP-1 compounds, eg, subjects at risk of developing non-insulin dependent diabetes mellitus (see WO 00/07617).
- Subjects with impaired glucose tolerance or impaired fasting glucose subjects whose weight exceeds about 25% of their normal weight to their height and physique, subjects undergoing partial pancreatic resection, one or more parents to non-insulin dependent diabetes mellitus
- Subjects with gestational diabetes, and subjects with acute or chronic pancreatitis are at risk of developing non-insulin dependent diabetes.
- the GLP included in the fusion polypeptide of the present invention is GLP-2
- treatment and prevention of gastric and intestinal related disorders such as osteoporosis and DPP-4 mediated symptoms
- treatment of newborns with impaired intestinal function And so on examples include ulcers, gastritis, digestive disorders, malabsorption syndrome, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, gluten-induced enteropathy or chronic digestive disorders.
- Other symptoms may also include radiation enteritis, infectious or post-infection enteritis, and small intestine damage due to toxic substances or other chemotherapy agents.
- the fusion polypeptide of the present invention is preferably administered once every four weeks, once every two weeks or once a week. Depending on the disease to be treated, the fusion polypeptide may need to be administered more frequently, such as 2-3 times a week.
- the present invention provides a polynucleotide encoding the fusion polypeptide, an expression vector comprising the polynucleotide, and a host cell comprising the expression vector.
- GLP-1 Glucagon like peptide-1
- DPP-4 DPP-4 enzyme in vivo
- the half-life is about 3 to 5 minutes. Since it is very short, there are many difficulties in developing as a drug, and many attempts have been made to increase the half-life in vivo.
- the present invention is to prepare a fusion polypeptide having excellent half-life and excellent activity by variously adjusting the IgD hinge region in hyFc5, and when increasing the amino acid of the IgD hinge region, these conditions can be satisfied. It was confirmed that there is a possibility.
- hyFc5 having a hinge consisting of 30 amino acids
- a hyFc9 having a hinge consisting of 40 amino acids (SEQ ID NO: 27) (Fig. 2)
- each 35 amino acids HyFc8 with a constructed hinge (SEQ ID NO: 26) and hyFc11 with a hinge consisting of 49 amino acids (SEQ ID NO: 28) were prepared.
- GLP-1 analog peptide was fused to hyFc9, hyFc8 and hyFc11, respectively, to GLP-1-hyFc9 (SEQ ID NO: 31), GLP-1-hyFc8 (SEQ ID NO: 30), and GLP-1-hyFc11 (SEQ ID NO: 32). ) Fusion polypeptides were prepared.
- GLP-2 Glucagon like peptide-2
- DPP-4 enzyme DPP-4 enzyme in vivo
- its half-life is very short (about 7 minutes)
- amino acid No. 2 a cleavage site by DPP-4 enzyme
- GLP-2-2G peptide SEQ ID NO: 45
- the substituted GLP-2-2G peptide is used as an adult short bowel syndrome treatment in a daily dosage form, but considering the need to continuously treat short bowel syndrome, development of a GLP-2 analogue having a longer half-life is required.
- the GLP-2-hyFc5 fusion polypeptide was prepared by fusing the hyFc5 polypeptide prepared in the present inventors' International Patent Publication No. WO2008-147143 to the GLP-2-2G analogue peptide (FIG. 3).
- the IgD hinge region was controlled to vary the length of the entire 64 amino acids, thereby preparing a fusion polypeptide having excellent activity while increasing the half-life of the GLP-2-2G peptide.
- hyFc5 having a hinge consisting of 30 amino acids is increased to prepare a hyFc9 having a hinge consisting of 40 amino acids by increasing the amino acid of the hinge region, and binding a GLP-2-2G peptide to the GLP-2-hyFc9 fusion poly Peptides were prepared (FIG. 3, SEQ ID NO: 48).
- hyFc8 with a hinge consisting of 35 amino acids and hyFc11 with a hinge consisting of 49 amino acids were prepared, and GLP-2-hyFc8 (SEQ ID NO: 47) and GLP-2, respectively, by combining GLP-2-2G peptides.
- -hyFc11 (SEQ ID NO: 49) fusion polypeptide was prepared.
- the results are expressed as the amount of protein remaining in the blood at each time and the area under the curve (AUC) value. As shown in Figure 5, it was confirmed that the AUC value of about 12 times in GLP-1-hyFc9 compared to GLP-1-hyFc5. Based on these results, it can be seen that GLP-1-hyFc9 can show more effective drug efficacy by increasing half-life more than GLP-1-hyFc5.
- GLP-1-hyFc9 and GLP-1-hyFc8 showed similar PK profiles, and GLP-1-hyFc8 showed slightly better levels. This was much better than the control group GLP-1-hyFc5. Based on these results, it could be seen that GLP-1-hyFc8 also showed more effective drug efficacy by increasing half-life.
- GLP-1-hyFc9 was targeted for further various efficacy.
- GLP-1-hyFc5 was used as a comparative group.
- rat serum stability tests were performed.
- test substances were diluted with rat serum, and each prepared sample was put in a 37 ° C thermostat and reacted for 0, 6, 10, 24, 48 hours, and then each substance was quantified by ELISA method.
- the results are expressed as the amount of protein remaining for each reaction time and the area under the curve (AUC) value of the time graph. As shown in Figure 7, it was confirmed that the AUC value of about 1.2-fold in GLP-1-hyFc9 compared to GLP-1-hyFc5. Based on these results, it was confirmed that GLP-1-hyFc9 was superior in serum stability to GLP-1-hyFc5.
- the results are expressed as the amount of protein remaining for each reaction time and the area under the curve (AUC) value of the time graph. As shown in FIG. 8, it was confirmed that DPP-4 resistance was improved by about 7 times or more in GLP-1-hyFc9 compared to GLP-1-hyFc5. On the basis of these results, it was found that GLP-1-hyFc9 is much superior in terms of stability to the DPP-4 enzyme capable of cleaving GLP-1.
- mice per group were dosed subcutaneously (SC), followed by glucose every 0, 1, 2, 4 and 8 days to measure changes in blood glucose to reduce blood glucose To check the ability.
- the results were obtained by measuring the change in blood glucose concentration from 1 minute to 180 minutes immediately after the administration of glucose on each measurement day, and the AUC values were calculated on each experimental day.
- the GLP-1-hyFc5 and GLP-1-hyFc9 AUC content is expressed as%.
- the GLP-1-linker-IgG4-mut and GLP-1-hyFc9 of the present invention structurally include a CH2-CH3 region of IgG4, so there is no safety problem due to CDC (Complement Dependent Cytotoxicity), but safety against ADCC. Because of this problem, we tried to determine the binding ability to Fc ⁇ receptors that play an important role in inducing ADCC, for this purpose, the binding test using Surface Plasmon Resonance (SPR, Bio-rad, #Proteon XPR36) was performed.
- SPR Surface Plasmon Resonance
- GLP-2-hyFc9 increasing intracellular cAMP was measured by stimulation of GLP-2-hyFc9.
- 293 cells expressing GLP-2R were incubated in 96 wells of 6 ⁇ 10 4 cells, and after 24 hours, fusion proteins were treated with 0, 0.1, 1, 3, 10, 100, and 300 nM concentrations. Induced membrane depolarization was measured by fluorescent Membrane Potential Dye.
- the activity of the GLP-2-2G peptide was 100%, the GLP-2-hyFc5 fusion protein exhibited 27% of the activity, indicating that the biological activity was greatly reduced.
- the 2-hyFc9 fusion protein showed 98% activity, indicating that inflammation-related biological activity was not reduced despite the fusion of hyFc9.
- GLP-2-hyFc9 was administered subcutaneously to compare the improvement in an inflammatory bowel disease model induced by Indomethachin.
- Six male Sprague Dawley Rats per group were treated with indomethacin 9 mg / kg on days 1 and 2 to induce inflammatory bowel disease.
- GLP-2-2G was treated twice with 50 nmol / kg twice a day from 3 to 8 days
- GLP-2-hyFc9 was treated with 50 nmol / kg once every two days. Necropsy was performed on day 9. The effects of inflammatory bowel disease were compared by comparing body weight, small intestine length, and inflammatory cytokine (TNF-a) expression in small intestine tissues.
- TNF-a inflammatory cytokine
- the group treated with GLP-2-hyFc9 at 80 nmol / kg / day for a total of four times had a diarrhea score lower than that of the group without treatment, and treated once with 320 nmol / kg / day.
- One group had a significantly lower diarrhea score than the group treated with four low doses.
- the mortality rate (27%) induced by 5-FU was reduced by 20% to 6.7% in the GLP-2-hyFc9-treated group (FIG. 17).
- GLP-2-hyFc9 has the effect of preventing diarrhea induced by chemotherapy.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
GLP-1(7-37) | GLP-1(7-36) | ||
서열번호 | 변이 위치 | 서열번호 | 변이 위치 |
2 | A8G | 14 | A8G |
3 | A8V | 15 | A8V |
4 | G22E | 16 | G22E |
5 | R36G | 17 | R36G |
6 | A8G G22E | 18 | A8G G22E |
7 | A8V G22E | 19 | A8V G22E |
8 | A8G R36G | 20 | A8G R36G |
9 | A8V R36G | 21 | A8V R36G |
10 | G22E R36G | 22 | G22E R36G |
11 | A8G G22E R36G | 23 | A8G G22E R36G |
12 | A8V G22E R36G | 24 | A8V G22E R36G |
Claims (22)
- (a) GLP(glucagon like peptide) 또는 이의 유사체; 및 (b) 면역글로불린 Fc 폴리펩타이드를 포함하는, 융합 폴리펩타이드로서,상기 면역글로불린 Fc 폴리펩타이드는 (i) 서열번호 25의 C-말단으로부터 35 내지 49개의 연속된 아미노산 서열로 이루어진, 분리된 IgD 힌지(hinge) 영역; 및 (ii) 서열번호 29의 아미노산 서열로 이루어진 CH2 및 CH3 영역을 포함하는 것인, 융합 폴리펩타이드.
- 제1항에 있어서, 상기 GLP는 GLP-1인 것인, 융합 폴리펩타이드.
- 제2항에 있어서, 상기 GLP-1은 서열번호 1 또는 13의 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제2항에 있어서, 상기 GLP-1의 유사체는 DPP-4 효소에 의한 절단 부위(cleavage site)가 변이된 것이고, 서열번호 2 내지 12 및 14 내지 24로 이루어진 군으로부터 선택되는 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제1항에 있어서, 상기 GLP는 GLP-2인 것인, 융합 폴리펩타이드.
- 제5항에 있어서, 상기 GLP-2는 서열번호 44의 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제5항에 있어서, 상기 GLP-2의 유사체는 DPP-4 효소에 의한 절단 부위(cleavage site)가 변이된 것이고, 서열번호 45 또는 46의 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제1항에 있어서, 상기 IgD 힌지 영역은 서열번호 26 내지 28로 이루어진 군으로부터 선택되는 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제1항에 있어서, 상기 융합 폴리펩타이드는, 면역글로불린 Fc 폴리펩타이드가 융합되지 않은 폴리펩타이드에 비해 증가된 반감기를 나타내는 것인, 융합 폴리펩타이드.
- 제1항에 있어서, 상기 융합 폴리펩타이드는 서열번호 30 내지 32으로 이루어진 군으로부터 선택되는 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제1항에 있어서, 상기 융합 폴리펩타이드는 서열번호 47 내지 49로 이루어진 군으로부터 선택되는 아미노산 서열로 이루어진 것인, 융합 폴리펩타이드.
- 제2항의 융합 폴리펩타이드를 유효성분으로 포함하는, 당뇨병 치료용 약학적 조성물.
- 당뇨병 치료를 위한 약제를 제조하기 위한, 제2항의 융합 폴리펩타이드의 용도.
- 제12항의 약학적 조성물을 개체에 투여하는 단계를 포함하는, 당뇨병 치료 방법.
- 제5항의 융합 폴리펩타이드를 유효성분으로 포함하는, 염증성 장질환, 항암화학요법에 의한 장 점막염 및 설사, 또는 단장 증후군 치료용 약학적 조성물.
- 염증성 장질환, 항암화학요법에 의한 장 점막염 및 설사, 또는 단장 증후군 치료를 위한 약제를 제조하기 위한, 제5항의 융합 폴리펩타이드의 용도.
- 제15항의 약학적 조성물을 개체에 투여하는 단계를 포함하는, 염증성 장질환, 항암화학요법에 의한 장 점막염 및 설사, 또는 단장 증후군 치료 방법.
- 제1항 내지 제11항 중 어느 한 항의 융합 폴리펩타이드를 코딩하는 폴리뉴클레오티드.
- 제18항에 있어서, 상기 폴리뉴클레오티드는 서열번호 41 내지 43으로 이루어진 군으로부터 선택된 핵산 서열로 이루어진 것인, 폴리뉴클레오티드.
- 제18항에 있어서, 상기 폴리뉴클레오티드는 서열번호 52 내지 54으로 이루어진 군으로부터 선택된 핵산 서열로 이루어진 것인, 폴리뉴클레오티드.
- 제18항의 폴리뉴클레오티드를 포함하는 발현 벡터.
- 제21항의 발현 벡터를 포함하는 숙주 세포.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES15875748T ES2757812T3 (es) | 2014-12-31 | 2015-12-31 | GLP y polipéptido fusionado a Fc híbrido de inmunoglobulina y su uso |
JP2017535812A JP6379300B2 (ja) | 2014-12-31 | 2015-12-31 | GLP及び免疫グロブリンハイブリッドFc融合ポリペプチド及びその用途 |
DK15875748T DK3241850T3 (da) | 2014-12-31 | 2015-12-31 | Fusionspolypeptid for glp og en hybrid immunoglobulin fc og anvendelsen deraf |
CN201580071643.8A CN107207618B (zh) | 2014-12-31 | 2015-12-31 | 包含glp和免疫球蛋白杂合fc的融合多肽及其用途 |
EP15875748.4A EP3241850B1 (en) | 2014-12-31 | 2015-12-31 | Glp and immunoglobulin hybrid fc fused polypeptide and use thereof |
PL15875748T PL3241850T3 (pl) | 2014-12-31 | 2015-12-31 | Polipeptyd fuzyjny zawierający glp i hybrydowy fc immunoglobuliny i jego zastosowanie |
US15/538,784 US10538569B2 (en) | 2014-12-31 | 2015-12-31 | Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof |
HK18105836.7A HK1246321A1 (zh) | 2014-12-31 | 2018-05-07 | 包含glp和免疫球蛋白雜合fc的融合多肽及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0195793 | 2014-12-31 | ||
KR20140195793 | 2014-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016108654A1 true WO2016108654A1 (ko) | 2016-07-07 |
Family
ID=56284700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/014542 WO2016108654A1 (ko) | 2014-12-31 | 2015-12-31 | Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10538569B2 (ko) |
EP (1) | EP3241850B1 (ko) |
JP (1) | JP6379300B2 (ko) |
KR (2) | KR101825048B1 (ko) |
CN (1) | CN107207618B (ko) |
DK (1) | DK3241850T3 (ko) |
ES (1) | ES2757812T3 (ko) |
HK (1) | HK1246321A1 (ko) |
PL (1) | PL3241850T3 (ko) |
TW (2) | TWI691513B (ko) |
WO (1) | WO2016108654A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019040399A1 (en) * | 2017-08-22 | 2019-02-28 | Shire-Nps Pharmaceuticals, Inc. | GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS |
WO2019090209A1 (en) * | 2017-11-06 | 2019-05-09 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 analogs and peptibodies for administration before during, or after surgery |
JP2020531002A (ja) * | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用igg fc変異体 |
JP2021509590A (ja) * | 2018-01-08 | 2021-04-01 | ジーアイ・イノベイション・インコーポレイテッドGi Innovation, Inc. | IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 |
RU2795594C2 (ru) * | 2017-11-06 | 2023-05-05 | Такеда Фармасьютикалс Ю.С.А., Инк. | Пептитело glp-2 для введения до, в течение или после хирургического вмешательства |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105801705B (zh) * | 2014-12-31 | 2019-05-24 | 天境生物科技(上海)有限公司 | 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途 |
US11491235B2 (en) | 2017-12-22 | 2022-11-08 | Kb Biomed Inc. | Oral gene carrier and use thereof |
WO2019125031A1 (ko) * | 2017-12-22 | 2019-06-27 | 케이비바이오메드 주식회사 | 경구용 유전자 전달체 및 이의 용도 |
KR102177339B1 (ko) * | 2017-12-22 | 2020-11-12 | 케이비바이오메드 주식회사 | 경구용 유전자 전달체 및 이의 용도 |
KR20190093165A (ko) | 2018-01-31 | 2019-08-08 | 주식회사 제넥신 | GLP-1 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드의 안정성 증진용 조성물 |
AU2019365212A1 (en) * | 2018-10-24 | 2021-04-29 | Shire-Nps Pharmaceuticals, Inc. | GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
CN113573739A (zh) * | 2019-03-08 | 2021-10-29 | 格纳西尼有限公司 | Glp-1融合蛋白及其用途 |
CA3140561A1 (en) * | 2019-05-14 | 2020-11-19 | Progen Co., Ltd. | A novel modified immunoglobulin fc fusion protein and use thereof |
BR112022018134A2 (pt) * | 2020-03-12 | 2022-11-22 | Sl Metagen | Proteína biespecífica nova e seu uso |
KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
AU2021248766A1 (en) * | 2020-04-03 | 2022-12-01 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising GLP-2 derivatives or long-acting conjugate of same |
WO2021230705A1 (ko) * | 2020-05-14 | 2021-11-18 | 주식회사 프로젠 | 신규 재조합 융합단백질 및 그의 용도 |
KR20220008788A (ko) * | 2020-07-14 | 2022-01-21 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도 |
US11610835B2 (en) | 2020-10-30 | 2023-03-21 | Taiwan Semiconductor Manufacturing Company Limited | Organic interposer including intra-die structural reinforcement structures and methods of forming the same |
CN114213524A (zh) * | 2021-11-08 | 2022-03-22 | 苏州博领干细胞再生医学有限公司 | 用于胰高血糖素样肽-2抗体检测的包被抗原及纯化方法、重组工程菌及培养方法 |
WO2023204556A1 (ko) * | 2022-04-18 | 2023-10-26 | 한미약품 주식회사 | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 |
KR20230156889A (ko) * | 2022-05-04 | 2023-11-15 | 이뮤노포지 주식회사 | GLP-1, 면역글로불린 Fc, 및 IGF-1을 포함하는 융합단백질 및 이의 용도 |
WO2024141054A1 (zh) * | 2022-12-30 | 2024-07-04 | 苏州康宁杰瑞生物科技有限公司 | 包含融合蛋白的药物组合物及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120189627A1 (en) * | 2007-11-02 | 2012-07-26 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
KR20140037961A (ko) * | 2007-05-30 | 2014-03-27 | 주식회사 제넥신 | 면역글로불린 융합 단백질 |
US20140377290A1 (en) * | 2011-12-30 | 2014-12-25 | Hanmi Science Co., Ltd. | Site-specific glp-2 conjugate using an immunoglobulin fragment |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
ATE251465T1 (de) | 1998-07-31 | 2003-10-15 | Novo Nordisk As | In-vitro stimulation von beta zellen vermehrung |
MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
BRPI0411132B8 (pt) * | 2003-06-12 | 2021-05-25 | Lilly Co Eli | protéina de fusão heteróloga e seus usos |
EP1924293A4 (en) * | 2005-08-06 | 2008-12-24 | Qinghua Wang | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I |
CN1935846A (zh) * | 2005-09-14 | 2007-03-28 | 王庆华 | 一种用于治疗糖尿病的融合蛋白及其制备方法和应用 |
US20070212355A1 (en) * | 2005-10-24 | 2007-09-13 | Baker Audrey E | GLP-2 Mimetibodies, Polypeptides, Compositions, Methods and Uses |
KR101333958B1 (ko) * | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질 |
-
2015
- 2015-12-30 KR KR1020150189957A patent/KR101825048B1/ko active IP Right Grant
- 2015-12-31 ES ES15875748T patent/ES2757812T3/es active Active
- 2015-12-31 US US15/538,784 patent/US10538569B2/en active Active
- 2015-12-31 CN CN201580071643.8A patent/CN107207618B/zh active Active
- 2015-12-31 TW TW106124909A patent/TWI691513B/zh active
- 2015-12-31 DK DK15875748T patent/DK3241850T3/da active
- 2015-12-31 PL PL15875748T patent/PL3241850T3/pl unknown
- 2015-12-31 JP JP2017535812A patent/JP6379300B2/ja active Active
- 2015-12-31 WO PCT/KR2015/014542 patent/WO2016108654A1/ko active Application Filing
- 2015-12-31 EP EP15875748.4A patent/EP3241850B1/en active Active
- 2015-12-31 TW TW104144638A patent/TWI685506B/zh active
-
2017
- 2017-09-05 KR KR1020170113402A patent/KR101825049B1/ko active IP Right Grant
-
2018
- 2018-05-07 HK HK18105836.7A patent/HK1246321A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140037961A (ko) * | 2007-05-30 | 2014-03-27 | 주식회사 제넥신 | 면역글로불린 융합 단백질 |
US20120189627A1 (en) * | 2007-11-02 | 2012-07-26 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
US20140377290A1 (en) * | 2011-12-30 | 2014-12-25 | Hanmi Science Co., Ltd. | Site-specific glp-2 conjugate using an immunoglobulin fragment |
Non-Patent Citations (2)
Title |
---|
GLAESNER ET AL.: "Engineering and Characterization of the Long-Acting Glucagon-like Peptide-1 Analogue LY2189265, an Fcfusion Protein", DIABETES/METABOLISM RESEARCH AND REVIEWS, vol. 26, no. 4, 2010, pages 287 - 296, XP055181624 * |
KIM ET AL.: "Fc Fusion to Glucagon-like Peptide-1 Inhibits Degradation by Human DPP-IV, increasing its Half-Life in Serum and inducing a Potent Activity for human GLP-1 Receptor Activation", BMB REPORTS, vol. 42, no. 4, 2009, pages 212 - 216, XP055460879 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020531002A (ja) * | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用igg fc変異体 |
JP7249492B2 (ja) | 2017-08-22 | 2023-03-31 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | Glp-2融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
CN111182916A (zh) * | 2017-08-22 | 2020-05-19 | 夏尔-Nps医药品有限公司 | Glp-2融合多肽及用于治疗及预防胃肠病状的用途 |
WO2019040399A1 (en) * | 2017-08-22 | 2019-02-28 | Shire-Nps Pharmaceuticals, Inc. | GLP-2 FUSION POLYPEPTIDES AND USES THEREOF FOR TREATING AND PREVENTING GASTROINTESTINAL DISORDERS |
JP2020531030A (ja) * | 2017-08-22 | 2020-11-05 | シャイア−エヌピーエス ファーマシューティカルズ インコーポレイテッド | Glp−2融合ポリペプチドならびに消化管の状態を処置および予防するための使用 |
JP2021502389A (ja) * | 2017-11-06 | 2021-01-28 | シャイア−エヌピーエス ファーマシューティカルズ インコーポレイテッド | 手術前、手術中または手術後に投与するためのglp−2類似体及びglp−2ペプチボディ |
CN111629745A (zh) * | 2017-11-06 | 2020-09-04 | 夏尔-Nps医药品有限公司 | 用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies) |
WO2019090209A1 (en) * | 2017-11-06 | 2019-05-09 | Shire-Nps Pharmaceuticals, Inc. | Glp-2 analogs and peptibodies for administration before during, or after surgery |
RU2795594C2 (ru) * | 2017-11-06 | 2023-05-05 | Такеда Фармасьютикалс Ю.С.А., Инк. | Пептитело glp-2 для введения до, в течение или после хирургического вмешательства |
US11660328B2 (en) | 2017-11-06 | 2023-05-30 | Takeda Pharmaceutical Company Limited | GLP-2 analogs and peptibodies for administration before, during or after surgery |
JP7296958B2 (ja) | 2017-11-06 | 2023-06-23 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | 手術前、手術中または手術後に投与するためのglp-2類似体及びglp-2ペプチボディ |
JP2021509590A (ja) * | 2018-01-08 | 2021-04-01 | ジーアイ・イノベイション・インコーポレイテッドGi Innovation, Inc. | IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 |
JP7128291B2 (ja) | 2018-01-08 | 2022-08-30 | ジーアイ・イノベイション・インコーポレイテッド | IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 |
JP2022176971A (ja) * | 2018-01-08 | 2022-11-30 | ジーアイ・イノベイション・インコーポレイテッド | IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 |
JP7488303B2 (ja) | 2018-01-08 | 2024-05-21 | ジーアイ・イノベイション・インコーポレイテッド | IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2018504111A (ja) | 2018-02-15 |
TW201636375A (zh) | 2016-10-16 |
TWI685506B (zh) | 2020-02-21 |
DK3241850T3 (da) | 2019-11-04 |
US10538569B2 (en) | 2020-01-21 |
JP6379300B2 (ja) | 2018-08-22 |
TWI691513B (zh) | 2020-04-21 |
EP3241850A1 (en) | 2017-11-08 |
ES2757812T3 (es) | 2020-04-30 |
HK1246321A1 (zh) | 2018-09-07 |
KR101825049B1 (ko) | 2018-02-05 |
TW201738278A (zh) | 2017-11-01 |
EP3241850A4 (en) | 2018-06-20 |
PL3241850T3 (pl) | 2020-01-31 |
CN107207618B (zh) | 2020-10-30 |
CN107207618A (zh) | 2017-09-26 |
KR20170106258A (ko) | 2017-09-20 |
US20170362293A1 (en) | 2017-12-21 |
KR101825048B1 (ko) | 2018-02-05 |
KR20160083810A (ko) | 2016-07-12 |
EP3241850B1 (en) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016108654A1 (ko) | Glp 및 면역글로불린 하이브리드 fc 융합 폴리펩타이드 및 이의 용도 | |
AU2016346864B2 (en) | Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same | |
AU2015268199B2 (en) | Composition for treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist | |
WO2015183038A1 (ko) | 지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물 | |
WO2012169798A2 (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same | |
KR101527233B1 (ko) | 선택적인 글루카곤 유사 펩티드-2(glp-2) 유사체 | |
WO2016108586A1 (ko) | 안정성이 증가된 글루카곤 유도체 | |
WO2012165915A2 (en) | Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate | |
WO2016114633A1 (en) | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same | |
WO2018088838A1 (en) | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins | |
WO2016006963A1 (en) | Insulin analogue | |
AU2015372767B2 (en) | Glucagon derivatives | |
WO2022245179A1 (en) | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist | |
WO2022010319A1 (ko) | 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 융합단백질 및 이의 용도 | |
WO2020184941A1 (en) | Glp-1 fusion proteins and uses thereof | |
WO2021182928A1 (ko) | 신규 이중 특이성 단백질 및 그의 용도 | |
WO2020017916A1 (en) | Pharmaceutical composition comprising polypeptide | |
WO2021162460A1 (ko) | 신규 비알코올성 간질환의 치료용 약학적 조성물 | |
WO2021230705A1 (ko) | 신규 재조합 융합단백질 및 그의 용도 | |
WO2019125003A1 (ko) | 경구용 유전자 전달체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15875748 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15538784 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017535812 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015875748 Country of ref document: EP |